G Griebel

Summary

Affiliation: Sanofi-Synthelabo Recherche
Country: France

Publications

  1. ncbi request reprint The effects of compounds varying in selectivity as 5-HT(1A) receptor antagonists in three rat models of anxiety
    G Griebel
    Sanofi Synthelabo, 31 Avenue Paul Vaillant Couturier, 92220, Bagneux, France
    Neuropharmacology 39:1848-57. 2000
  2. ncbi request reprint Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist
    Claudine Serradeil-Le Gal
    Exploratory Research Department, Sanofi Synthelabo Recherche, Toulouse, Montpellier et Bagneux, France
    J Pharmacol Exp Ther 300:1122-30. 2002
  3. ncbi request reprint Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents
    Guy Griebel
    Sanofi Aventis Recherche, Bagneux, France
    Biol Psychiatry 57:261-7. 2005
  4. ncbi request reprint Effects of SR48968, a selective non-peptide NK2 receptor antagonist on emotional processes in rodents
    G Griebel
    CNS Research Department, Sanofi Synthelabo, 31, avenue Paul Vaillant Couturier, 92220 Bagneux, France
    Psychopharmacology (Berl) 158:241-51. 2001
  5. ncbi request reprint Characterization of the profile of neurokinin-2 and neurotensin receptor antagonists in the mouse defense test battery
    G Griebel
    CNS Research Department, Sanofi Synthelabo Recherche, 31 Avenue Paul Vaillant Couturier, 92220, Bagneux, France
    Neurosci Biobehav Rev 25:619-26. 2001
  6. pmc Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders
    Guy Griebel
    Sanofi Synthelabo Recherche, avenue P V Couturier, 92220 Bagneux, France
    Proc Natl Acad Sci U S A 99:6370-5. 2002
  7. ncbi request reprint SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms
    Guy Griebel
    CNS Research Department, Sanofi Synthelabo, 92220 Bagneux, France
    CNS Drug Rev 9:3-20. 2003
  8. ncbi request reprint 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Charac
    Guy Griebel
    Central Nervous System Research Department, Sanofi Synthelabo, Bagneux, France
    J Pharmacol Exp Ther 301:333-45. 2002
  9. ncbi request reprint The vasopressin V1b receptor as a therapeutic target in stress-related disorders
    Guy Griebel
    Sanofi Synthelabo Recherche, Bagneux, France
    Curr Drug Targets CNS Neurol Disord 2:191-200. 2003
  10. ncbi request reprint Pharmacological studies on synthetic flavonoids: comparison with diazepam
    G Griebel
    CNS Research Department, Synthelabo Recherche, Bagneux, France
    Neuropharmacology 38:965-77. 1999

Collaborators

Detail Information

Publications61

  1. ncbi request reprint The effects of compounds varying in selectivity as 5-HT(1A) receptor antagonists in three rat models of anxiety
    G Griebel
    Sanofi Synthelabo, 31 Avenue Paul Vaillant Couturier, 92220, Bagneux, France
    Neuropharmacology 39:1848-57. 2000
    ..The data are discussed in relation to the possible relevance of species differences in 5-HT(1A) receptor function and the nature of the anxiety response studied...
  2. ncbi request reprint Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist
    Claudine Serradeil-Le Gal
    Exploratory Research Department, Sanofi Synthelabo Recherche, Toulouse, Montpellier et Bagneux, France
    J Pharmacol Exp Ther 300:1122-30. 2002
    ..It represents a unique tool for exploring the functional role of V1b receptors and deserves to be clinically investigated in the field of stress and anxiety...
  3. ncbi request reprint Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents
    Guy Griebel
    Sanofi Aventis Recherche, Bagneux, France
    Biol Psychiatry 57:261-7. 2005
    ..The endocannabinoid system has been implicated in the modulation of emotional processes...
  4. ncbi request reprint Effects of SR48968, a selective non-peptide NK2 receptor antagonist on emotional processes in rodents
    G Griebel
    CNS Research Department, Sanofi Synthelabo, 31, avenue Paul Vaillant Couturier, 92220 Bagneux, France
    Psychopharmacology (Berl) 158:241-51. 2001
    ..It has been suggested that tachykinin NK(2) receptor antagonists may have therapeutic utility in anxiety and/or depressive disorders...
  5. ncbi request reprint Characterization of the profile of neurokinin-2 and neurotensin receptor antagonists in the mouse defense test battery
    G Griebel
    CNS Research Department, Sanofi Synthelabo Recherche, 31 Avenue Paul Vaillant Couturier, 92220, Bagneux, France
    Neurosci Biobehav Rev 25:619-26. 2001
    ..e. risk assessment), they may have a potential against some forms of anxiety disorders which involve adaptative responses to extreme stress stimuli (e.g. direct confrontation with the threat stimulus)...
  6. pmc Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders
    Guy Griebel
    Sanofi Synthelabo Recherche, avenue P V Couturier, 92220 Bagneux, France
    Proc Natl Acad Sci U S A 99:6370-5. 2002
    ..These findings point to a role for vasopressin in the modulation of emotional processes via the V(1b) receptor, and suggest that its blockade may represent a novel avenue for the treatment of affective disorders...
  7. ncbi request reprint SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms
    Guy Griebel
    CNS Research Department, Sanofi Synthelabo, 92220 Bagneux, France
    CNS Drug Rev 9:3-20. 2003
    ..SL651498 represents a promising alternative to agents currently used for the treatment of anxiety disorders and muscle spasms without the major side effects seen with classical BZs...
  8. ncbi request reprint 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Charac
    Guy Griebel
    Central Nervous System Research Department, Sanofi Synthelabo, Bagneux, France
    J Pharmacol Exp Ther 301:333-45. 2002
    ..Together, these data indicate that SSR125543A shows good activity in acute and chronic tests of unavoidable stress exposure, suggesting that it may have a potential in the treatment of depression and some forms of anxiety disorders...
  9. ncbi request reprint The vasopressin V1b receptor as a therapeutic target in stress-related disorders
    Guy Griebel
    Sanofi Synthelabo Recherche, Bagneux, France
    Curr Drug Targets CNS Neurol Disord 2:191-200. 2003
    ..Altogether, these findings suggest that V(1b) receptor antagonists might be useful as a treatment for major depression and stress disorders that result from traumatic events...
  10. ncbi request reprint Pharmacological studies on synthetic flavonoids: comparison with diazepam
    G Griebel
    CNS Research Department, Synthelabo Recherche, Bagneux, France
    Neuropharmacology 38:965-77. 1999
    ..Furthermore, they question the contribution of BZ-omega receptors to the behavioral effects of 6-bromoflavone and 6-bromo-3'-nitroflavone...
  11. ncbi request reprint SL651498: an anxioselective compound with functional selectivity for alpha2- and alpha3-containing gamma-aminobutyric acid(A) (GABA(A)) receptors
    G Griebel
    CNS Research Department, Discovery Research, Sanofi Synthelabo, Bagneux, France
    J Pharmacol Exp Ther 298:753-68. 2001
    ....
  12. ncbi request reprint New evidence that the pharmacological effects of benzodiazepine receptor ligands can be associated with activities at different BZ (omega) receptor subtypes
    G Griebel
    CNS Research Department, Synthelabo Recherche, 31, avenue Paul Vaillant Couturier, F 92220 Bagneux, France
    Psychopharmacology (Berl) 146:205-13. 1999
    ..It has been suggested that different BZ (omega) receptor subtypes may mediate distinct behavioural effects of BZ receptor ligands...
  13. ncbi request reprint Limited anxiolytic-like effects of non-benzodiazepine hypnotics in rodents
    G Griebel
    CNS Research Department, Synthelabo Recherche, Bagneux, France
    J Psychopharmacol 12:356-65. 1998
    ..In particular, the anxiety-reducing potential of the omega1-BZD receptor selective compounds is limited to certain anxiety measures and may be confounded and/or masked by behavioural suppression...
  14. ncbi request reprint A comparative study of the effects of selective and non-selective 5-HT2 receptor subtype antagonists in rat and mouse models of anxiety
    G Griebel
    CNS Research Department, Synthelabo Recherche, Bagneux, France
    Neuropharmacology 36:793-802. 1997
    ....
  15. ncbi request reprint SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit
    J P Terranova
    Sanofi Synthelabo Recherche, CNS Research, 371 Rue du Pr Blayac, 34184 Montpellier, France
    Psychopharmacology (Berl) 181:134-44. 2005
    ....
  16. ncbi request reprint Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats
    N Salome
    Sanofi Aventis, Department of Psychopharmacology, 31 Avenue Paul Vaillant Couturier, Bagneux 92220, France
    Psychopharmacology (Berl) 187:237-44. 2006
    ....
  17. ncbi request reprint Differences in anxiolytic-like profile of two novel nonbenzodiazepine BZ (omega) receptor agonists on defensive behaviors of mice
    G Griebel
    CNS Research Department, Synthelabo Recherche, Bagneux, France
    Pharmacol Biochem Behav 62:689-94. 1999
    ..Although RWJ-46771 significantly modified most defensive behaviors, the effects may have been confounded by decreases in locomotor activity...
  18. ncbi request reprint Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression
    R Alonso
    Sanofi Synthelabo Recherche, Rue du Professeur J Blayac, Montpellier, France
    Mol Psychiatry 9:278-86, 224. 2004
    ....
  19. ncbi request reprint Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function
    R Steinberg
    Central Nervous System Research Department, Sanofi Synthelabo Recherche, Montpellier, France
    J Pharmacol Exp Ther 299:449-58. 2001
    ..These data suggest that NK2 receptor blockade may constitute a novel mechanism in the treatment of depression and CRF-related disorders...
  20. ncbi request reprint Behavioural profiles in the mouse defence test battery suggest anxiolytic potential of 5-HT(1A) receptor antagonists
    G Griebel
    Synthelabo Recherche, Bagneux, France
    Psychopharmacology (Berl) 144:121-30. 1999
    ..Compounds varying in selectivity as 5-HT1A receptor antagonists have recently been reported to produce anxiolytic-like effects comparable to those of benzodiazepines in the mouse elevated plus-maze procedure...
  21. ncbi request reprint Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone
    G Griebel
    CNS Research Department, Synthelabo Recherche, Bagneux, France
    Psychopharmacology (Berl) 138:55-66. 1998
    ....
  22. ncbi request reprint Behavioral effects of acute and chronic fluoxetine in Wistar-Kyoto rats
    G Griebel
    CNS Research Department, Sanofi Synthelabo, Bagneux, France
    Physiol Behav 67:315-20. 1999
    ..Overall, these findings provided little evidence that WKY rats may represent a valid model of stress-related disorders...
  23. ncbi request reprint Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils
    N Salome
    Department of Psychopharmacology, Sanofi Aventis, 31 av Paul Vaillant Couturier, 92220 Bagneux, France
    Pharmacol Biochem Behav 83:533-9. 2006
    ..p.). Diazepam and SSR240600 were inactive in this paradigm. In conclusion, the present study indicates further that NK2 and NK3 receptor antagonists may have therapeutic potential in the clinical management of anxiety and depression...
  24. ncbi request reprint Behavioral effects of phenelzine in an experimental model for screening anxiolytic and anti-panic drugs: correlation with changes in monoamine-oxidase activity and monoamine levels
    G Griebel
    Synthelabo Recherche, Bagneux, France
    Neuropharmacology 37:927-35. 1998
    ..These results suggest that the effects of phenelzine may be due mainly to its effects on the 5-HT system and presumably related to the full inhibition of MAO-A and/or MAO-B...
  25. ncbi request reprint CCK receptor antagonists in animal models of anxiety: comparison between exploration tests, conflict procedures and a model based on defensive behaviours
    G Griebel
    , Bagneux, France
    Behav Pharmacol 8:549-60. 1997
    ....
  26. ncbi request reprint Study of the modulatory activity of BZ (omega) receptor ligands on defensive behaviors in mice: evaluation of the importance of intrinsic efficacy and receptor subtype selectivity
    G Griebel
    Synthelabo Recherche, Bagneux, France
    Prog Neuropsychopharmacol Biol Psychiatry 23:81-98. 1999
    ....
  27. ncbi request reprint Comparison of the pharmacological properties of classical and novel BZ-omega receptor ligands
    G Griebel
    CNS Research Department, Sanofi Synthelabo, Bagneux, France
    Behav Pharmacol 10:483-95. 1999
    ..This suggests that BZ receptor modulation of anxiety may involve BZ receptor subtypes other than BZ-omega 1...
  28. ncbi request reprint Differences in anxiety-related behaviours and in sensitivity to diazepam in inbred and outbred strains of mice
    G Griebel
    CNS Research Department, Sanofi Synthelabo, 31, avenue Paul Vaillant Couturier, 92220 Bagneux, France
    Psychopharmacology (Berl) 148:164-70. 2000
    ..Natural strain differences exist in mice for behavioural traits such as emotional reactivity...
  29. ncbi request reprint Cortico-limbic circuitry for conditioned nicotine-seeking behavior in rats involves endocannabinoid signaling
    E Kodas
    Department of Psychopharmacology, Sanofi Aventis Research and Development, 31 Avenue Paul Vaillant Couturier, 92220, Bagneux, France
    Psychopharmacology (Berl) 194:161-71. 2007
    ..The endocannabinoid system plays an important role in conditioned drug seeking, but the neuronal mechanisms involved in this behavior are unclear...
  30. ncbi request reprint Orphanin FQ, a novel neuropeptide with anti-stress-like activity
    G Griebel
    CNS Research Department, Synthelabo Recherche, 31, avenue Paul Vaillant Couturier, 92220 Bagneux, France
    Brain Res 836:221-4. 1999
    ..e., risk assessment), while it may play a role in the adaptative responses to unavoidable or extreme stress stimuli...
  31. ncbi request reprint SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats
    D Boulay
    CNS Department, Sanofi Synthelabo Recherche, Discovery Research, 31 Ave P Vaillant Couturier, 92220 Bagneux, France
    Neuropharmacology 46:1121-9. 2004
    ....
  32. ncbi request reprint Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat
    David H Overstreet
    Department of Psychiatry and Bowles Center for Alcohol Studies, CB 7178, 429 Taylor Bldg, University of North Carolina, Chapel Hill, NC 27599 7178, USA
    Pharmacol Biochem Behav 82:223-7. 2005
    ..These findings confirm the antidepressant-like potential of SSR149415 and suggest that it may also have anxiolytic effects. It is likely that the strategy of testing selective vasopressin V1b receptor antagonists will be fruitful...
  33. ncbi request reprint Antidepressant-like effects of the corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, in a DRL-72 s schedule in the rat
    Caroline Louis
    CNS Research Department, Sanofi Aventis, Bagneux, France
    Neuropsychopharmacology 31:2180-7. 2006
    ....
  34. ncbi request reprint Disruption of the prepulse inhibition of the startle reflex in vasopressin V1b receptor knockout mice: reversal by antipsychotic drugs
    Nobuaki Egashira
    Department of Neuropharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan
    Neuropsychopharmacology 30:1996-2005. 2005
    ..The results of the present study indicate that V1bR may be involved in the regulation of PPI of the startle reflex. The V1bR has been considered an important molecular target for the development of antipsychotic drugs...
  35. ncbi request reprint CB1 receptor antagonists for the treatment of nicotine addiction
    Caroline Cohen
    Sanofi Aventis, CNS Research Department, 31 Avenue Paul Vaillant Couturier, 92220 Bagneux, France
    Pharmacol Biochem Behav 81:387-95. 2005
    ..Rimonabant may be considered as a potential alternative to the current substitutive treatments of nicotine addiction and may offer a new hope for the treatment of smokers who wish to quit...
  36. ncbi request reprint Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic
    Ronan Depoortere
    CNS Department, Sanofi Synthelabo Recherche, Bagneux, France
    Neuropsychopharmacology 30:1963-85. 2005
    ..By targeting one of the primary causes of schizophrenia (hypoglutamatergy), it is expected to be efficacious not only against positive but also negative symptoms, cognitive deficits, and comorbid depression/anxiety states...
  37. ncbi request reprint Long-term impaired memory following predatory stress in mice
    Wissam El Hage
    EA3248 and IFR135, Universite Francois Rabelais, Faculté Sciences et Techniques, Parc Grandmont, 37200 Tours, France
    Physiol Behav 87:45-50. 2006
    ..This animal model of unique exposure of mice to unavoidable predatory stimuli has proven to be a useful model for the study of reactions to traumatic stress...
  38. ncbi request reprint SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia
    Philippe Pichat
    Central Nervous System Research Department, Sanofi Aventis, Bagneux, France
    Neuropsychopharmacology 32:17-34. 2007
    ..The antidepressant-like properties of SSR180711 are of added interest, considering the high prevalence of depressive symptoms in schizophrenic patients...
  39. ncbi request reprint SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile
    Bruno Biton
    Central Nervous System Research Department, Sanofi Aventis, Bagneux, France
    Neuropsychopharmacology 32:1-16. 2007
    ..Together, these results demonstrate that SSR180711 is a selective and partial agonist at human, rat and mouse alpha7 n-AChRs, increasing glutamatergic neurotransmission, ACh release and LTP in the hippocampus...
  40. ncbi request reprint Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders
    Jeanne Stemmelin
    Sanofi Aventis, CNS Research, Bagneux, France
    Neuropsychopharmacology 33:574-87. 2008
    ..Taken as a whole, these findings indicate that the pharmacological stimulation of beta3 adrenoceptors may represent an innovative approach for the treatment of anxiety and depressive disorders...
  41. ncbi request reprint Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models
    Caroline Louis
    Sanofi Aventis Research and Development, Psychopharmacology Department, 31 Avenue Paul Vaillant Couturier, 92220 Bagneux, France
    Pharmacol Biochem Behav 89:36-45. 2008
    ..Together, these results suggest further that the NK2 receptor may represent an attractive target for the treatment of both depressive and anxiety disorders...
  42. doi request reprint Confirmation of antidepressant potential of the selective beta3 adrenoceptor agonist amibegron in an animal model of depression
    David H Overstreet
    Department of Psychiatry and Center for Alcohol Studies, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7178, USA
    Pharmacol Biochem Behav 89:623-6. 2008
    ..Thus, amibegron had a selective antidepressant-like effect in this study, confirming its antidepressant potential...
  43. doi request reprint Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal
    Alexandre Surget
    U930, INSERM, Universite Francois Rabelais de Tours, Tours, France
    Biol Psychiatry 64:293-301. 2008
    ..We investigated causality between changes in hippocampal neurogenesis and the effects of both chronic stress and chronic ADs...
  44. doi request reprint Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia
    Denis Boulay
    Sanofi Aventis, CNS Department, 31 Avenue Paul Vaillant Couturier, Bagneux, France
    Pharmacol Biochem Behav 91:47-58. 2008
    ..o.), respectively. These findings suggest that SSR103800 may have a therapeutic potential in the management of the core symptoms of schizophrenia and comorbid depression states...
  45. ncbi request reprint Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders
    Guy Griebel
    CNS Research Department, Sanofi Aventis, 31 Avenue Paul Vaillant Couturier, Bagneux, 92220, France
    Curr Pharm Des 11:1549-59. 2005
    ..Altogether, these findings suggest that V(1b) receptor antagonists represent a promising alternative to agents currently used for the treatment of depression and some forms of anxiety disorders...
  46. ncbi request reprint An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders
    Claudine Serradeil-Le Gal
    Sanofi Synthelabo Recherche, Exploratory Research Department, 195 route d Espagne, 31036 Toulouse Cedex, France
    CNS Drug Rev 11:53-68. 2005
    ..Clinical trials are in progress, they will hopefully demonstrate its therapeutical potential for treating stress-related disorders...
  47. ncbi request reprint 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemi
    Danielle Gully
    Exploratory Research Department, Sanofi Synthelabo, Toulouse, France
    J Pharmacol Exp Ther 301:322-32. 2002
    ..c.v. injection of 1 microg of CRF in gerbils (ID(50) = approximately 10 mg/kg p.o.). Altogether, these data indicate that SSR125543A is a potent, selective, and orally active CRF(1) receptor antagonist...
  48. ncbi request reprint SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]-4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin 1 receptor: II. Neurochemical and b
    Regis Steinberg
    C N S Research Department, Sanofi Synthelabo Recherche, Montpellier, France
    J Pharmacol Exp Ther 303:1180-8. 2002
    ..Finally, SSR240600 counteracted the increase in body temperature induced by isolation stress. In conclusion, SSR240600 is able to antagonize various NK1 receptor-mediated as well as stress-mediated effects in the guinea pig...
  49. ncbi request reprint The Mouse Defense Test Battery: pharmacological and behavioral assays for anxiety and panic
    D Caroline Blanchard
    Pacific Biomedical Research Center, University of Hawaii, 1993 East West Road, Honolulu 96822, USA
    Eur J Pharmacol 463:97-116. 2003
    ..This review suggests that the Mouse Defense Test Battery is a sensitive and appropriate tool for preclinical evaluation of drugs potentially effective against defense-related disorders such as anxiety and panic...
  50. ncbi request reprint Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice
    Cecile Ducottet
    EA 3248 Psychobiologie des Emotions, IFR120 Imagerie et exploration fonctionnelles, Faculte des Sciences and Techniques, UFR Sciences et Techniques, Universite Francois Rabelais, Parc de Grandmont Avenue Monge, F 37200, Tours, France
    Prog Neuropsychopharmacol Biol Psychiatry 27:625-31. 2003
    ..Chronic treatment with antalarmin (10 mg/kg ip) and fluoxetine (10 mg/kg ip) led to an improvement of CMS-induced modifications. These results suggest that CRF(1) receptor antagonists may represent potential antidepressants...
  51. ncbi request reprint Functional and pharmacological characterization of the first specific agonist and antagonist for the V1b receptor in mammals
    Claudine Serradeil-Le Gal
    Sanofi Synthelabo Recherche, Toulouse, France
    Stress 6:199-206. 2003
    ..Interestingly, SSR149415 displays potent anxiolytic and antidepressant-like activities, indicating that this new class of drugs has a promising therapeutical potential in the treatment of stress-related disorders, anxiety and depression...
  52. ncbi request reprint Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders
    Andrew Holmes
    Section on Behavioral Science and Genetics, National Institute of Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892, USA
    Trends Pharmacol Sci 24:580-8. 2003
    ....
  53. ncbi request reprint Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415
    Jeanne Stemmelin
    Sanofi Synthelabo Research, Department of Psychopharmacology, CNS Research Department, Bagneux, France
    Neuropsychopharmacology 30:35-42. 2005
    ..These findings suggest that V1b receptors located in the lateral septum participate in the antidepressant- but not the anxiolytic-like action of SSR149415 in rats...
  54. ncbi request reprint Impaired memory following predatory stress in mice is improved by fluoxetine
    Wissam El Hage
    EA3248 Psychobiologie des Emotions and IFR120, Faculté Sciences et Techniques, Parc Grandmont, 37200 Tours, France
    Prog Neuropsychopharmacol Biol Psychiatry 28:123-8. 2004
    ..Taken together, these findings indicate that this animal model of exposure of mice to unavoidable predatory stimuli produces early cognitive changes analogous to those seen in patients with acute stress disorder (ASD)...
  55. ncbi request reprint Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716)
    Caroline Cohen
    Sanofi Synthelabo Recherche, Bagneux, France
    Neuropsychopharmacology 30:145-55. 2005
    ..Rimonabant, which has been shown previously to reduce nicotine self-administration, may be effective not only as an aid for smoking cessation but also in the maintenance of abstinence...
  56. ncbi request reprint Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression
    David H Overstreet
    Department of Psychiatry, Center for Alcohol Studies, CB 7178, 3009 Thurston Bowles Bldg, University of North Carolina, Chapel Hill, NC 27599 7178, USA
    Eur J Pharmacol 497:49-53. 2004
    ..Together, these findings indicate that the CRF(1) receptor antagonist SSR125543 has both antidepressant- and anxiolytic-like effects in the Flinders Sensitive Line rats...
  57. ncbi request reprint AVP V1b selective antagonist SSR149415 blocks aggressive behaviors in hamsters
    Robert J Blanchard
    Department of Psychology, University of Hawaii, 2430 Campus Road, Honolulu, HI 96822, USA
    Pharmacol Biochem Behav 80:189-94. 2005
    ..These findings agree with previous research on V1b receptor effects in suggesting that antagonism of this receptor may be useful in modulating a range of emotional responses to highly stressful or threatening conditions...
  58. ncbi request reprint Contribution of GABAA receptor subtypes to the anxiolytic-like, motor, and discriminative stimulus effects of benzodiazepines: studies with the functionally selective ligand SL651498 [6-fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-yl-carbonyl)-2,9-dihydro-1H-
    Stephanie C Licata
    Harvard Medical School, New England Primate Research Center, Southborough, MA 01772, USA
    J Pharmacol Exp Ther 313:1118-25. 2005
    ..Moreover, a compound with reduced efficacy at alpha(1) GABA(A) and/or alpha(5) GABA(A) receptors may lack some of the motor and subjective effects associated with conventional BZs...
  59. ncbi request reprint Effects of the CRF1 antagonist SSR125543A on aggressive behaviors in hamsters
    Catherine Farrokhi
    Department of Psychology, University of Hawaii, 2430 Campus Road, Honolulu, HI 96822, USA
    Pharmacol Biochem Behav 77:465-9. 2004
    ....
  60. ncbi request reprint Conditioning and residual emotionality effects of predator stimuli: some reflections on stress and emotion
    D Caroline Blanchard
    Pacific Biomedical Research Center, University of Hawaii, Honolulu, HI 96822, USA
    Prog Neuropsychopharmacol Biol Psychiatry 27:1177-85. 2003
    ..That such stimuli fail to support rapid aversive conditioning suggests the need for a reanalysis of the characteristics required for an effective aversive US...
  61. doi request reprint Defensive responses to predator threat in the rat and mouse
    D Caroline Blanchard
    University of Hawaii, Honolulu, Hawaii, USA
    Curr Protoc Neurosci . 2005
    ..These factors indicate the need for selective, reliable, and convenient tests of defensiveness to predators and predator odors using rat and mouse subjects...